Senate Approves S.3187 the Food and Drug Administration Safety and Innovation Act S. 3187

Media Contacts
Nasima Hossain


Statement of Nasima Hossain, Public Health Advocate on the Senate vote of the 2012 Food and Drug Administration Safety and Innovation Act:

The Senate moved rapidly toward passage of a five-year user fee reauthorization for the Food and Drug Administration on Thursday, with strong bipartisan support. We commend the Senate for agreeing to include Senator Grassley’s amendment to provide deadlines for the issuance of certain regulations and to require a GAO report on the implementation of the clinical trial registration and reporting requirements under the Public Health Service Act. This will ensure pharmaceutical and medical device companies are  accountable and provide more information about their clinical trials, thereby ensuring greater safety for consumers.

However we are disappointed that key amendments U.S. PIRG supported introduced by Senator Sanders, and Senator Bingaman that would have protected consumers from the deceitful practices of the pharmaceutical industry and give greater access to affordable generic  drugs did not pass.

The Senate bill also passed without making adequate progress in preventing unsafe devices from entering the market. This is of great concern to us in view of the 1/2 billion recall of medical devices during 2010 and 2011 and the death of a toddler infected fatally by a contaminated  medical swab in December 2010.

As the House readies itself for reauthorization H.R.565, their version of this bill, U.S. PIRG will actively be advocating on behalf of consumers to ensure that the medical devices and drug review process is strengthened.